Cochrane · systematic review · CD009818
Interleukin‐2 as an adjunct to antiretroviral therapy for HIV‐positive adults
Onwumeh, J, Okwundu, CI, Kredo, T · Cochrane Database of Systematic Reviews · 2017 · Cochrane Library
Infectious DiseasesAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
6
current version
GRADE rated
5
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 1 · 16.7%Very low 0 · 0%Low 1 · 16.7%Moderate 1 · 16.7%High 3 · 50%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
'Summary of findings' table 1
Population: HIV‐positive adults
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
All‐cause mortality | RR 0.97 [0.8, 1.17] | 6 studies · 6565 participants | High |
CD4 cell count | no estimate extracted | 21 studies · 7600 participants | Ungraded |
HIV RNA levels less than 50 cells/mL | RR 0.97 [0.81, 1.15] | 5 studies · 805 participants | High |
HIV RNA levels less than 500 cells/mL | RR 0.96 [0.82, 1.12] | 4 studies · 5929 participants | High |
Opportunistic infections | RR 0.79 [0.55, 1.13] | 7 studies · 6141 participants | Low Downgraded: imprecision |
Adverse events (grade 3 or 4) | RR 1.47 [1.1, 1.96] | 6 studies · 6291 participants | Moderate Downgraded: imprecision |